Table 4.
Demographic and clinical characteristics of the Study 2 sample (N=125)
| Full Sample | Test-retest sample (n=61) | |
|---|---|---|
|
| ||
| Variable | M(SD or %) | M(SD or %) |
| Age (years) | 17.8 (3.57) | 18.03 (3.82) |
| Age at diagnosis (years) | 10.14 (5.87) | 11.13 (5.42) |
| Time since Tx completion (years) | 6.44 (4.46) | 5.76 (3.83) |
| Sex | ||
| Male | 58 (46%) | 27 (44%) |
| Female | 68 (54%) | 34 (55%) |
| Gender (US sample only) | ||
| Boy/Man | 48 (47%) | 27 (44%) |
| Girl/Woman | 52 (51%) | 34 (55%) |
| Non-binary | 1 (1%) | 0 (0%) |
| Gender fluid/ Gender queer | 1 (1%) | 0 (0%) |
| Diagnosis | ||
| ALL | 47 (37%) | 19 (31%) |
| AML | 9 (7%) | 5 (8%) |
| Hodgkin’s Lymphoma | 17 (14%) | 9 (15%) |
| Non-Hodgkin’s Lymphoma | 15 (12%) | 8 (13%) |
| Ewing Sarcoma | 5 (4%) | 3 (5%) |
| Osteosarcoma | 4 (3%) | 2 (3%) |
| Soft tissue or other sarcoma | 4 (3%) | 3 (5%) |
| Germ cell tumor | 3 (2%) | 3 (5%) |
| Neuroblastoma | 4 (3%) | 1 (2%) |
| Wilms’ tumor | 5 (4%) | 1 (2%) |
| Brain / CNS tumor | 2 (2%) | 1 (2%) |
| Carcinoma | 2 (2%) | 1 (2%) |
| Ovarian cancer | 4 (3%) | 2 (3%) |
| Hepatoblastoma | 1 (1%) | 0 (0%) |
| Acute Promyelocytic Lymphoma | 1 (1%) | 0 (0%) |
| Multiple cancers | 2 (2%) | 2 (3%) |
| Race | ||
| Caucasian/White | 65 (52%) | 23 (38%) |
| Asian America | 30 (24%) | 23 (38%) |
| American Indian / Alaskan Native / Native Canadian | 1 (1%) | 0 (0%) |
| Hawaiian Native or Pacific Islander | 1 (1%) | 0 (0%) |
| Mixed race | 11 (9%) | 5 (8%) |
| Other | 16 (13%) | 8 (13%) |
| Ethnicity (US sample only) | ||
| Not Hispanic or Latino | 69 (68%) | 45 (74%) |
| Hispanic or Latino | 32 (25%) | 16 (26%) |